Recent studies sight β-
adrenergic receptor (AR) antagonists as novel therapeutic agents for
melanoma, as they may reduce
disease progression. Here within, we evaluated the expression of β-ARs in a series of human cutaneous melanocytic lesions, and studied the effect of their endogenous agonists,
norepinephrine (NE) and
epinephrine (E), on primary and metastatic human
melanoma cell lines. Using immunohistochemistry, we found that both β1- and β2-ARs are expressed in tissues from benign melanocytic naevi, atypical naevi and
malignant melanomas and that expression was significantly higher in malignant tumours.
Melanoma cell lines (human A375 primary
melanoma cell line and human Hs29-4T metastatic
melanoma cell lines) also expressed β1- and β2-ARs by measuring transcripts and
proteins. NE or E increased
metalloprotease-dependent motility, released
interleukin-6 and 8 (IL-6, IL-8) and
vascular endothelial growth factor (
VEGF). These effects of
catecholamines were inhibited by the unselective β-AR antagonist
propranolol. The role of soluble factors elicited by
catecholamines seemed pleiotropic as
VEGF synergized with NE increased
melanoma invasiveness through 3D barriers, while
IL-6 participated in stromal fibroblast activation towards a myofibroblastic phenotype. Our results indicate that NE and E produce in vitro via β-ARs activation a number of biological responses that may exert a pro-tumorigenic effect in
melanoma cell lines. The observation that β-ARs are upregulated in
malignant melanoma tissues support the hypothesis that circulating
catecholamines NE and E, by activating their receptors, favour
melanoma progression in vivo.